Evidence map›Paper›PMID 41982370›Full record

ArticleCureus2026

miRNA-Processing Gene Variants and Neuroblastoma Susceptibility: A Pilot Case-Control Study.

Ioannis Kyriakidis, Iordanis Pelagiadis, Georgia Martimianaki, Maria Stratigaki, Nikolaos Katzilakis, Eftichia Stiakaki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ioannis KyriakidisDepartment of Pediatric Hematology-Oncology and Autologous Hematopoietic Stem Cell Transplantation Unit, University Hospital of Heraklion and Laboratory of Blood Diseases and Childhood Cancer Biology, School of Medicine, University of Crete, Heraklion, GRC.
Iordanis PelagiadisDepartment of Pediatric Hematology-Oncology and Autologous Hematopoietic Stem Cell Transplantation Unit, University Hospital of Heraklion and Laboratory of Blood Diseases and Childhood Cancer Biology, School of Medicine, University of Crete, Heraklion, GRC.
Georgia MartimianakiDepartment of Pediatric Hematology-Oncology and Autologous Hematopoietic Stem Cell Transplantation Unit, University Hospital of Heraklion and Laboratory of Blood Diseases and Childhood Cancer Biology, School of Medicine, University of Crete, Heraklion, GRC.
Maria StratigakiDepartment of Pediatric Hematology-Oncology and Autologous Hematopoietic Stem Cell Transplantation Unit, University Hospital of Heraklion and Laboratory of Blood Diseases and Childhood Cancer Biology, School of Medicine, University of Crete, Heraklion, GRC.
Nikolaos KatzilakisDepartment of Pediatric Hematology-Oncology and Autologous Hematopoietic Stem Cell Transplantation Unit, University Hospital of Heraklion and Laboratory of Blood Diseases and Childhood Cancer Biology, School of Medicine, University of Crete, Heraklion, GRC.
Eftichia StiakakiDepartment of Pediatric Hematology-Oncology and Autologous Hematopoietic Stem Cell Transplantation Unit, University Hospital of Heraklion and Laboratory of Blood Diseases and Childhood Cancer Biology, School of Medicine, University of Crete, Heraklion, GRC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeuroblastoma (NB) is the most common extracranial solid tumor in children, but the inherited factors influencing susceptibility are not fully understood. Given the link between defective microRNA biogenesis and aggressive NB, germline variants in key miRNA-processing genes are plausible candidate modifiers. This pilot case-control study aimed to assess whether five selected SNPs in MATERIALS AND

methodsThis exploratory case-control study included 200 children from Crete, Greece, comprising 25 with NB and 175 healthy controls recruited during routine health visits. Five SNPs in

resultsIn the adjusted primary analyses,

conclusionsThis pilot study suggests that genetic variations in the miRNA-processing pathway may affect NB susceptibility. Further research involving larger, ethnically diverse cohorts, along with expanded genotype-expression analyses and functional validation, is essential before clinical or prognostic applications can be established.

Indexed as

argonautedicerdroshagenetic susceptibilitymicrornaneuroblastomapolymorphism

Identifiers

PMID41982370
PMCPMC13071081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.